Alzheimer's disease (AD) is a progressive, neurodegenerative disorder with unclear aetiology. Cognitive impairment in AD might be associated with altered serotonergic system. The aim of the study was to determine platelet serotonin (5-HT) concentrations and platelet monoamine oxidase type B (MAO-B) activity in patients with different severity of AD. Platelet 5-HT concentrations and MAO-B activity were determined spectrofluorimetrically in 74 female patients with AD (NINCDS-ADRDA, DSM-IV-TR criteria), subdivided according to the Mini Mental State Examination (MMSE) scores in three groups with a) 23 patients in early (MMSE scores 19-24), b) 23 patients in middle (MMSE 10-18), and c) 28 patients in late (MMSE 0-9) phase of AD, and in 49 age-matched healthy women. Platelet 5-HT concentrations and MAO-B activity were similar between all patients with AD and healthy subjects, but were significantly lower in patients in the late phase of AD than in other phases of AD, and in healthy controls. The significant correlations were found between MMSE scores and platelet 5-HT concentrations, MAO-B activity and age. Lower platelet 5-HT concentration and MAO-B activity in the late phase of AD suggested that these markers might indicate severity and/or clinical progress of AD.
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Introduction
Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder, with still unclear aetiology (Forsyth and Ritzline, 1998) . The neurobiological background of AD includes the accumulation of amyloid plaques and neurofibrillary tangles in the brain, and dysfunction in the cholinergic function (Pakaski and Kalman, 2008) . The alterations in the other neurotransmitter systems, especially serotonergic and dopaminergic, are also thought to be responsible for the cognitive deficits and the behavioral disturbances observed in patients with AD (Garcia-Alloza et al., 2005; Terry et al., 2008) . Serotonin (5-hydroxytryptamine, 5-HT) has an important role in the regulation of the synaptic function, neurite outgrowth, synaptogenesis and cell survival (Terry et al., 2008) . It regulates different physiological functions (circadian rhythm, food intake, locomotion, thermoregulation, nociception, sexual activity), behaviors (Lucki, 1998) , and cognitive functions such as learning and memory (Mattson et al., 2004) . The decrease in the brain concentration of 5-HT and its main metabolites 5-hydroxyindoleacetic acid, the loss of serotonergic 5-HT1A receptors in the hippocampus and nuclei raphe (Kepe et al., 2006) , and 5-HT2 receptors in cerebral cortex (Blin et al., 1993) were found in patients with AD. Genetic investigations suggested the role of serotonergic 5-HT2A and 5-HT2C receptors polymorphisms in the development of behavioral and psychological symptoms of AD (Pritchard et al., 2008) . Recently, a beneficial effect of the additional treatment with selective 5-HT reuptake inhibitor, fluoxetine, on daily living and functioning was found in AD patients treated with rivastigmine (Mowla et al., 2007) .
Blood platelets have been proposed as an easy obtainable limited peripheral model for some processes in the presynaptic (5-HT reuptake, monoamine oxidase type B/MAO-B/activity) and postsynaptic (5-HT2A receptors binding) parts of the central serotonergic neurons (Camacho and Dimsdale, 2000; Mendelson, 2000) , and for the expression of the brain amyloid precursor protein (Cattabeni et al., Progress in Neuro-Psychopharmacology & Biological Psychiatry 33 (2009) 
